Growth Hormone Adjunct Therapy Boosts Oocyte Yield and Live‑Birth Rates in Assisted Reproductive Technology

The Question

Clinicians have long wondered whether supplementing assisted reproductive technology (ART) cycles with growth hormone (GH) can meaningfully improve the number and quality of retrieved oocytes, as well as downstream pregnancy outcomes.

The Experiment

Volevodz and colleagues from the Endocrinology Research Centre compiled and evaluated existing clinical reports on GH use in ART. The authors performed a narrative review, summarizing findings across multiple studies rather than generating new patient data. The abstract does not disclose a specific cohort size, indicating that the article itself does not present original participants.

The review focused on four primary outcomes:

What They Found

The authors report that, across the surveyed literature, GH adjunct therapy is linked to higher oocyte yield, better‑graded embryos, and increased pregnancy and live‑birth rates compared with standard ART protocols. No numerical effect sizes or p‑values appear in the abstract.

Why It Matters

GH stimulates hepatic production of insulin‑like growth factor‑1 (IGF‑1), a hormone that promotes granulosa‑cell proliferation and enhances follicular responsiveness to gonadotropins. By amplifying this axis, GH may extend the window of follicular development, yielding more competent oocytes. Improved embryo quality can translate into higher implantation efficiency, which directly impacts the likelihood of a live birth.

Study Limitations

• The article synthesizes published reports without presenting new experimental data, limiting the ability to control for heterogeneity among source studies.


• Sample characteristics and dosing regimens vary widely across the cited literature, making it difficult to isolate the effect of GH alone.


• Absence of quantitative metrics in the abstract prevents assessment of statistical significance or effect magnitude.

Practical Application

It is too early to apply this to a personal protocol, because the review does not specify a GH dose, administration schedule, or safety monitoring framework. Future work must include randomized, double‑blind trials with clearly defined dosing, adequate participant numbers, and standardized outcome reporting before practitioners can responsibly integrate GH adjunct therapy into ART cycles.

Disclaimer: This article is for informational and educational purposes only. The information presented does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before modifying your diet, supplementation, or exercise routines. The scientific studies cited reflect the state of knowledge at their publication date and may be subject to revision.